BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Sep. 16, 2009
View Archived Issues
Alcon Paying Up to $589M for EsbaTech Eye Business
Underlining the current vogue for antibody-based technologies, Alcon Inc. is acquiring the ophthalmology business of ESBATech AG for $150 million in cash plus up to $439 million in potential milestones. (BioWorld International)
Read More
ArGEN-X Snares $13.8M for Llama-based Antibody Platform
Read More
Differentiation Control Switch Sheds Light on Cancer Triggers
Read More
Troubled Arpida's Stock Surges as Evolva Rides to the Rescue
Read More
Antisoma Faces Good Problem; Hiring for 2 Potential Launches
Read More
Mutabilis Spins Out a FAB Company for MRSA Work
Read More
Other News To Note
Read More